Table II.
IL-15/IL-15 Rα-IgG1-Fc.
Research group | IL-15 superagonsit | Effect on NK cells | Effect on CD8+ T cells | Improved survival and/or tumor clearance of | Anti-tumor effects mediated by |
---|---|---|---|---|---|
Epardaud et al | IL-15/IL-15 Ra- IgG1-Fc | ↑number | ↑number, IFN granzyme B -γ and | Metastatic melanoma and pancreatic tumor | Tumor-resident, but neither circulating CD8+ nor NK or NKT cells |
Dubois et al | IL-15/IL-15 Ra- IgG1-Fc | ↑proliferation and killing | ↑proliferation, especially memory subset | Metastatic melanoma | NK cells, but not T or B cells |
Rubinstein et al | IL-15/IL-15 Ra- IgG1-Fc | ↑proliferation | ↑proliferation, especially antigenspecific memory subset | NA | NA |
Guo et al | IL-15/IL-15 Ra- IgG1-Fc | ↑number, CD69, IFN-γ, granzyme B and perforin | ↑number, especially memory subset, and granzyme | NA | NA |
Stoklasek et al | IL-15/IL-15 Ra- IgG1-Fc | ↑proliferation | ↑proliferation, especially memory subset; differentiation to effector and long-term memory subsets | Metastatic melanoma | NA |
Huntington et al | IL-15/IL-15 Rα- IgG1-Fc | ↑reconsitution of human NK cells in humanized mice; CD69, Bcl- 2 and Bcl-xl; | ↑reconsitution of human CD8 T cells + in humanized mice | NA | NA |
Wu et al | IL-15/IL-15 Ra- IgG1-Fc | ↑number and granzyme B | ↑number | NA | NA |
FAP: fibroblast activation protein.